#1BIONTAINER by BIONTECH Introducing a scalable manufacturing solution for Africa Press Conference 16 February 2022#2BIONTECH This slide presentation includes forward-looking statements This presentation contains forward-looking statements within the meaning of the Private Securities Litigation Reform Act of 1995. These forward-looking statements may include, but may not be limited to, direct or indirect statements concerning: the ability of BioNTech to produce, deliver and install mRNA container manufacturing facilities for the African continent, including the ability to meet all necessary infrastructure, technology and regulatory requirements; the ability of BioNTech to reach an agreement with potential collaboration partners in Africa to establish an end-to-end manufacturing network in Africa; the development of quality assurance capabilities to remotely support manufacturing sites in Africa; the scale-up of local know-how and training in Africa; BioNTech's malaria, tuberculosis and other infectious disease vaccine development programs; timing for selecting clinical candidates for these programs and the commencement of a clinical trial, as well as any data readouts; the nature of the collaboration with the African Union, the Africa CDC, and the WHO; the development of sustainable RNA vaccine capacities, production and supply solutions on the African continent and the nature, timing, and feasibility of these solutions; the potential safety and efficacy of the product candidates; and BioNTech's anticipated market opportunity and size for its product candidates the rate and degree of market acceptance of BioNTech's investigational medicines, if approved; BioNTech's efforts to combat COVID-19; the collaboration between BioNTech and Pfizer to develop a COVID-19 vaccine (including qualitative assessments of available data, potential benefits, expectations for clinical trials, supply agreements and the timing of delivery of doses thereunder, efforts to help ensure global equitable access to the vaccine, the anticipated timing of regulatory submissions, regulatory approvals or authorizations and anticipated manufacturing, distribution and supply). Any forward-looking statements in this presentation are based on BioNTech current expectations and beliefs of future events, and are subject to a number of risks and uncertainties that could cause actual results to differ materially and adversely from those set forth in or implied by such forward-looking statements. These risks and uncertainties include, but are not limited to: discussions with regulatory agencies regarding timing and requirements for additional clinical trials; and the ability to produce comparable clinical results in future clinical trials. For a discussion of these and other risks and uncertainties, see BioNTech's Annual Report on Form 20-F for the Year Ended December 31, 2020, filed with the SEC on March 30, 2021, which is available on the SEC's website at www.sec.gov. All information in this presentation is as of the date of the release, and BioNTech undertakes no duty to update this information unless required by law.#3Marburg is our largest manufacturing site BioNTech's Marburg site is one of the largest mRNA vaccine manufacturing sites Supply of mRNA for more than 1.2 bn doses of the COVID-19 vaccine in 2021 as part of a European manufacturing network 50% boost in staff planned in 2022 (+ 250 jobs) EUR 50 million to be invested in Marburg site in 2022 BIONTECH#4Manufacturing innovations made in Marburg Manufacturing Center State-of-the-art, large- scale GMP-compliant vaccine production Innovation Center Development of novel manufacturing solutions DIODOKSAT BIONTECH Excellence Center Quality control for remote manufacturing#5BIONTECH BioNTainers: Introduction of a turnkey, scalable solution BIONTAINER by BIONTECH#6Key facts on BioNTainer set-up in Africa VAN Scope Structure Container size Shipment Production volume (initial) Production Quality control Local infrastructure Technical autonomy Scope of application 12 containers 6 containers = 1 module > 1 drug substance (DS) module > 1 drug product (DP) module ISO sized (2.6m x 2.4m x 12m) Shipped via freighter, truck and train E.g. approx. 50 million doses of the Pfizer-BioNTech COVID-19 vaccine BioNTech jointly with local support BioNTech jointly with local support E.g. logistics, quality control labs, quality control set-up, warehousing, cold and frozen storage Fully self-sufficient Single to multi-drug production & clinical trials BIONTECH#7Two BioNTainers as core of mRNA vaccine production BIOREACTOR MINDAN DEIND ИНСИН CINC DDDDD DOS NAMM 1 mRNA production NA mRNA 2 mRNA purification & concentration Module 1 6 containers make up one BioNTainer for drug substance BANI 24 3 Drug product formulation Module 2 6 containers make up one BioNTainer for drug product B. B 4 Filling & packaging BIONTECH Local partners#8Key questions and answers Why now? What challenges can be addressed? How is quality control supported? Why a joint effort? What is the bigger picture? What comes next? BIONTECH#9The time is now to facilitate access to mRNA In a connected world, a global approach is required to address public health issues NUM mRNA is a versatile drug class to potentially develop various vaccines A Technology, automation and digitalization allow for new solutions Learnings from the COVID-19 pandemic BIONTECH & The pandemic has shown the power of collaboration and joint efforts#10A sustainable solution for mRNA vaccine production The challenge Establishing GMP production of mRNA is complex and requires overcoming challenges at many levels Technical solutions for manufacturing sites must comply with internationally harmonized GMP standards Complex mRNA manufacturing process with high quality standards BIONTECH Highly qualified personnel required to ensure transfer process and system maintenance The solution Turnkey package that includes modular production units, GMP-compliant setup and personnel training Container-based "Plug & Play" approach with modular design, standardized equipment and software components GMP process implementation and maintenance facilitated by validation packages, automation, digital solutions, local and global quality control Training of local employees with planned hand- over of site to support sustainable supply within African Union as well as development of local biotechnology industry#11High-quality vaccine manufacturing is our priority Approved suppliers to provide raw materials Transfer of know- how and trained personnel to build manufacturing capabilities in a sustainable and safe way 280 components from 86 suppliers in 19 countries 50,000 steps from beginning of a Pfizer-BioNTech COVID-19 vaccine batch to bulk filling Note: Figures refer to the Pfizer-BioNTech COVID-19 vaccine and are exemplary. Local quality control on site to ensure the safety and quality of the production process 40 individual quality control tests for each finished vaccine batch BIONTECH Global support by quality control center in Marburg to support the operations of all BioNTainers 24/7 support and monitoring of processes#12A joint effort to build a mRNA manufacturing network The BioNTainer solution ensures: Partner contribution: Utilities BIONTAINER by BIONTECH M Indicative manufacturing network Potential partners for fill & finish BIONTAINER by BIONTECH M ---- H - M - H M - Acceleration of knowledge and technology transfer Rapid set-up of new mRNA manufacturing nodes for licensed mRNA vaccines Pandemic preparedness & other use cases Sustainability through maintenance and updating 4 = GMP BIONTECH 56 A Power supply, water connections, wastewater treatment, internet/network Access to talent Trainees, technicians, professionals Regulatory framework In collaboration with e.g. WHO, Africa CDC/AMA Operation permit Legal permission to run production Fill & finish capacity Local F&F for end-to-end manufacturing in Africa Logistics & supply Enabling manufacturing and dissemination#13A solution optimized for quality, speed and sustainability ✓Quality Speed Sustainability Proven efficacy and safety of mRNA GMP-compliant facility and processes Multiple quality controls to release vaccine batches Turnkey facility to shorten set-up time Replicable transfer of processes Training and 24/7 support BIONTECH mRNA is a new drug class suitable for many diseases Adaptation for future needs through modular facility design Decentralized process updates and continuous improvement 00#14CON What is next in 2022 Finalize the planning and initial assets for the new facility in the African Union Start of construction of first manufacturing facility in African Union in mid-2022 First BioNTainer expected to be shipped in H2/2022 Regulatory framework in alignment with international standards e.g. WHO and Africa CDC/AMA Evaluation of additional use cases and products for BioNTainers (clinical trials and regional pandemic preparedness) BIONTAINER by BIONTECH 89 BIONTECH#15Further media material: link